Biometry is an easy to use breath test for asthma
Sensor + Device + App
Find the Right Medication
Monitor Risk of Attack
What we measure
FeNO, a biomarker of airway inflammation that is reduced by anti-inflammatory medications. Elevated levels indicate risk of an asthma attack that is independent of symptoms. The biomarker was added to the Global Initiative for Asthma Guidelines in 2017.
Over 82% of patients who had a severe asthma attack thought their disease was controlled.1Biometry changes perceptions about asthma severity by showing patients when they are at risk for an attack regardless of symptoms.
Biomarker is elevated. Patient is at risk of having an attack even if they don't have symptoms.
Patients understand they need to use their controller medications even if they feel fine.
Biomarker levels are reduced within 1 day. Patients can visualize the anti-inflammatory effect of the drug and how it reduces risk of an attack.
Physicians and Payers
Most patients don’t adhere to asthma therapy. When patients do use their inhalers, over 70% make a critical error that prevents the drug from reaching their lungs and having a therapeutic effect.2 This leads to poorly controlled asthma which costs between $893 and $7,138 per patient per year depending on severity.3,4
Physicians don’t know if asthma symptoms and attacks are caused by non-adherence, misuse of inhaler, or disease severity requiring more potent drugs. This results in approximately 50% of medical treatment being either unnecessary or preventable.1-5
Biometry's data provides objective information to physicians to prevent attacks and reduce unnecessary treatment.
Adherence testing with ongoing monitoring
How it works
- Price D. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. npj Prim Care Respir Med. 2014. Severe asthma attacks requiring oral steroids, ER or Hospitalization
- Price D. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. J Allergy Clin Immunol Pract. 2017
- Ivanova J. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol. 2012
- Optum Chronic Condition Management. https://cdn-aem.optum.com/content/dam/optum3/optum/en/resources/fact-sheets/conditionmanagement_product_sheet_clin_mgmt.pdf. Accessed August 22, 2017.
- Bateman ED. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study (GOAL). Am J Respir Crit Care Med. 2004